Stockscreener 앱 받기
1.57
4.67%
0.07
전일 마감가:
$1.50
열려 있는:
$1.5
하루 거래량:
74,851
Relative Volume:
1.05
시가총액:
$82.39M
수익:
-
순이익/손실:
$-4.61M
주가수익비율:
-12.52
EPS:
-0.1254
순현금흐름:
$-3.10M
1주 성능:
+5.37%
1개월 성능:
+0.00%
6개월 성능:
-14.21%
1년 성능:
-28.96%
1일 변동 폭
$1.50
$1.60
1주일 범위
$1.42
$1.60
52주 변동 폭
$1.42
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.57 | 79.77M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Piper Sandler | Overweight |
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma (OKYO) director awarded options on 3,500 common shares - Stock Titan
OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85 - Stock Titan
Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares - Stock Titan
OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85 - Stock Titan
OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners - Stock Titan
OKYO Pharma Slips 1.85% as Shares Test Key Support LevelTrend Following Picks - newsline.com
OKYO Pharma (OKYO) Retreats Toward Support as Biotech Sector Faces HeadwindsInverse ETF Flow - newsline.com
OKYO Pharma (OKYO) director reports detailed stock option grants - Stock Titan
OKYO H2'25 Earnings: EPS estimate is (0.08) USD - TradingView
OKYO Pharma (OKYO) director discloses stock and option holdings - Stock Titan
[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership - Stock Titan
OKYO Pharma Edges Lower, Holds Steady Near Key Support LevelStop Loss Guidance - newsline.com
OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma (OKYO) Edges Higher on Modest Gains, Holds Above Key SupportSentiment Divergence - The Legal Advocate
OKYO H2'25 Earnings: revenue estimate is 0 USD - TradingView
OKYO Pharma Shares Edge Higher as Biotech Momentum BuildsMFI Overbought - The Legal Advocate
OKYO Pharma expands scientific advisory board with cornea expertICYMI - Proactive financial news
OKYO Pharma Ltd (OKYO) CFO details equity and option positions - Stock Titan
OKYO Pharma (OKYO) CEO discloses multiple stock option positions - Stock Titan
What Makes OKYO Pharma (OKYO) a New Buy Stock - Yahoo Finance
Should I buy OKYO Pharma (OKYO) - Zacks Investment Research
Okyo Pharma Appoints Marta Sacchetti, MD, Ph.D., to Scientific Advisory Board - VisionMonday.com
OKYO Pharma adds Marta Sacchetti to scientific advisory board By Investing.com - Investing.com India
OKYO Pharma appoints Marta Sacchetti to advisory board By Investing.com - Investing.com South Africa
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment - Proactive financial news
OKYO Pharma adds ophthalmology specialist Marta Sacchetti to Scientific Advisory Board - Yahoo! Finance Canada
OKYO Pharma Adds European Eye Disease Expert to Advisory Board as Urcosimod Advances in Neuropathic Corneal Pain - TipRanks
OKYO Pharma adds Marta Sacchetti to scientific advisory board - Investing.com
OKYO Pharma appoints Marta Sacchetti to advisory board - Investing.com
OKYO Pharma (OKYO) deepens NCP program with new advisory board expert - Stock Titan
OKYO Pharma Limited Expands Scientific Advisory Board with Appointment of Marta Sacchetti - marketscreener.com
Point72 and Steven A. Cohen report 0% stake in OKYO (NASDAQ: OKYO) - Stock Titan
Woodline Partners reports 7.0% stake in OKYO Pharma (NASDAQ: OKYO) - Stock Titan
Sirenia Capital (OKYO) files Schedule 13G reporting 7.7% ownership - Stock Titan
Number of shareholders of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Number of shareholders of OKYO Pharma Limited – GETTEX:OK11 - TradingView
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Up 31.9% in April - MarketBeat
OKYO Pharma to present at Eyecelerator, share urcosimod data at ARVO annual meeting - Proactive financial news
OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver - TipRanks
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May - The Manila Times
OKYO Pharma (NASDAQ: OKYO) showcases urcosimod NCP data at Eyecelerator and ARVO - Stock Titan
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 25.0% in March - MarketBeat
Aug Action: How does OKYO Pharma Limited compare to its peers - baoquankhu1.vn
Piper Sandler Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Sentiment: Is OKYO Pharma Limited a turnaround storyMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Gap Down: Can OKYO Pharma Limited beat the S P 5002026 Chart Watch & Safe Entry Point Alerts - baoquankhu1.vn
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
OKYO Pharma to hold advisory board meeting at ASCRS conference By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting - Sahm
Small cap wrap: Replenish Nutrients, OKYO Pharma, Bit Digital, Record Resources… - Proactive financial news
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):